Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Feb 28, 2023 7:37am
70 Views
Post# 35308943

RE:RE:RE:RE:New Press Release - Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management

RE:RE:RE:RE:New Press Release - Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset ManagementNo one would argue that a qualified auditors opinion is a good thing but I am not sure how meaningful this one is since this agreement insures THTX will get the second tranche of the loan and they should be able to easily meet the main condition left for getting it, that they have $75 million in sales. So, while the auditors technically need to put the going concern note in their opinion, there is actually not much of a risk at all of THTX failing to meet its financial obligations. This agreement basically assures the needed funding to make sure no such problems actually arise. But, since the cash to cover the convert is not in hand yet, the auditors pretty much had to offer the qualified opinion.
<< Previous
Bullboard Posts
Next >>